{"id":491053,"date":"2024-10-25T12:54:24","date_gmt":"2024-10-25T10:54:24","guid":{"rendered":"https:\/\/innovationorigins.com\/?p=491053"},"modified":"2024-10-25T12:54:24","modified_gmt":"2024-10-25T10:54:24","slug":"eindhoven-breakthrough-e50-million-euro-for-walking-revolution-paraplegic-patients","status":"publish","type":"post","link":"https:\/\/ioplus.nl\/archive\/en\/eindhoven-breakthrough-e50-million-euro-for-walking-revolution-paraplegic-patients\/","title":{"rendered":"Eindhoven breakthrough: \u20ac50 million for walking revolution paraplegic patients"},"content":{"rendered":"\n

Eindhoven-based Onward Medical has raised \u20ac50 million<\/a> for their groundbreaking spinal cord stimulator. Germany’s Ottobock, a leader in orthopedic technology, is investing and acquiring 10% shares. The stimulator, which aims to restore movement to spinal cord patients, is about to enter the US market. This capital will stimulate research over the next two years. With fewer than 12 employees in Eindhoven and a core operation in Lausanne, former G&A winner Onward Medical demonstrates the global ambition of Dutch medtech innovation.<\/p>\n\n\n\n

Most of this financial boost comes from the German company Ottobock, a leading player in prosthetics and orthopedic devices. With this investment, Ottobock takes a tenth of the shares in Onward Medical. This confirms the position of trust Onward has established within the medical technology sector.<\/p>\n\n\n

<\/a>
<\/div><\/div>
ONWARD Medical provides breakthrough treatment for patients with partial spinal cord injury<\/div>
A new therapy by ONWARD Medical, which uses electrical stimulation, shows promising results in improving hand and arm function in people with incomplete spinal cord.<\/div><\/div><\/div>\n\n\n

Strategic cooperation with Ottobock<\/h2>\n\n\n\n

The cooperation between Onward Medical and Ottobock is not new. Previously, the companies announced they were joining forces. The recent investment strengthens this bond and allows Onward Medical to develop and market its therapies worldwide. With the support of an established name like Ottobock, Onward can accelerate and improve its innovative treatments.<\/p>\n\n\n\n

Ottobock, with more than a century of experience developing solutions for people with reduced mobility, sees great potential in Onward’s therapy approaches for people with spinal cord injuries. It shows a clear commitment to innovation and progress in the industry.<\/p>\n\n\n\n

The US market is in the crosshairs<\/h2>\n\n\n\n

After years of investment in research and development, Onward Medical is ready to enter the U.S. market with its spinal cord stimulator. The first products are expected to be available within a few months, an important step for the company to generate revenue from its inventions.<\/p>\n\n\n\n

This step is crucial, as Onward has invested mainly in its products’ development phase. In March, a previous capital injection of \u20ac20 million showed dwindling financial reserves. However, with the current \u20ac50 million investment, the company seems to be back on track for further development and commercialization.<\/p>\n\n\n

<\/a>
<\/div><\/div>
ONWARD Medical raises \u20ac20 million to advance spinal cord stimulation therapies<\/div>
In a significant financial move, ONWARD Medical, a pioneering medical technology company, has successfully secured \u20ac20 million. <\/div><\/div><\/div>\n\n\n

The road to commercial success<\/h2>\n\n\n\n

Onward Medical is focused on commercial success. Approving their regulatory filing with the FDA for the ARC-EX System in the US is a major milestone. The company is also preparing for regulatory submission in Europe. These steps are essential for the eventual commercialization of their products.<\/p>\n\n\n\n

Ottobock’s investment highlights Onward’s belief in innovation and their shared ambition to drive breakthrough innovation within the industry. With the combined strengths of both companies, they can significantly impact the quality of life of people with spinal cord injury.<\/p>\n","protected":false},"excerpt":{"rendered":"

Eindhoven-based Onward Medical has raised \u20ac50 million for their groundbreaking spinal cord stimulator. Germany’s Ottobock, a leader in orthopedic technology, is investing and acquiring 10% shares. The stimulator, which aims to restore movement to spinal cord patients, is about to enter the US market. This capital will stimulate research over the next two years. With […]<\/p>\n","protected":false},"author":1744,"featured_media":505129,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[83907,42],"tags":[85292,65181],"location":[6763],"article_type":[36684],"serie":[],"archives":[],"internal_archives":[],"reboot-archive":[82868],"class_list":["post-491053","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bio-en","category-sustainability-nl","tag-ga","tag-onward-medical","location-netherlands","article_type-news","reboot-archive-bio"],"blocksy_meta":[],"acf":{"subtitle":"Former G&A winner Onward Medical raises \u20ac50 million from investors.","text_display_homepage":false},"author_meta":{"display_name":"Aafke Eppinga","author_link":"https:\/\/ioplus.nl\/archive\/author\/aafke-eppinga\/"},"featured_img":"https:\/\/ioplus.nl\/archive\/wp-content\/uploads\/2024\/03\/Screenshot-2024-03-22-at-07.59.35.png","coauthors":[],"tax_additional":{"categories":{"linked":["BIO+<\/a>","Sustainability<\/a>"],"unlinked":["BIO+<\/span>","Sustainability<\/span>"]},"tags":{"linked":["G&A<\/a>","Onward Medical<\/a>"],"unlinked":["G&A<\/span>","Onward Medical<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on October 25, 2024","modified":"Updated on October 25, 2024"},"absolute_dates_time":{"created":"Posted on October 25, 2024 12:54 pm","modified":"Updated on October 25, 2024 12:54 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts\/491053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/users\/1744"}],"replies":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/comments?post=491053"}],"version-history":[{"count":0,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts\/491053\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media\/505129"}],"wp:attachment":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media?parent=491053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/categories?post=491053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/tags?post=491053"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/location?post=491053"},{"taxonomy":"article_type","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/article_type?post=491053"},{"taxonomy":"serie","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/serie?post=491053"},{"taxonomy":"archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/archives?post=491053"},{"taxonomy":"internal_archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/internal_archives?post=491053"},{"taxonomy":"reboot-archive","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/reboot-archive?post=491053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}